These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. A low molecular weight PSMA-based fluorescent imaging agent for cancer. Chen Y; Dhara S; Banerjee SR; Byun Y; Pullambhatla M; Mease RC; Pomper MG Biochem Biophys Res Commun; 2009 Dec; 390(3):624-9. PubMed ID: 19818734 [TBL] [Abstract][Full Text] [Related]
28. Novel multifunctional Kwon YD; Lee JY; La MT; Lee SJ; Lee SH; Park JH; Kim HK Eur J Med Chem; 2020 Mar; 189():112099. PubMed ID: 32014792 [TBL] [Abstract][Full Text] [Related]
29. A modular strategy to prepare multivalent inhibitors of prostate-specific membrane antigen (PSMA). Banerjee SR; Pullambhatla M; Shallal H; Lisok A; Mease RC; Pomper MG Oncotarget; 2011 Dec; 2(12):1244-53. PubMed ID: 22207391 [TBL] [Abstract][Full Text] [Related]
30. Assessment of an 18F-labeled phosphoramidate peptidomimetic as a new prostate-specific membrane antigen-targeted imaging agent for prostate cancer. Lapi SE; Wahnishe H; Pham D; Wu LY; Nedrow-Byers JR; Liu T; Vejdani K; VanBrocklin HF; Berkman CE; Jones EF J Nucl Med; 2009 Dec; 50(12):2042-8. PubMed ID: 19910433 [TBL] [Abstract][Full Text] [Related]
31. The Effects of Monosodium Glutamate on PSMA Radiotracer Uptake in Men with Recurrent Prostate Cancer: A Prospective, Randomized, Double-Blind, Placebo-Controlled Intraindividual Imaging Study. Harsini S; Saprunoff H; Alden T; Mohammadi B; Wilson D; Bénard F J Nucl Med; 2021 Jan; 62(1):81-87. PubMed ID: 32385167 [TBL] [Abstract][Full Text] [Related]
32. Enhancing Treatment Efficacy of Kuo HT; Merkens H; Zhang Z; Uribe CF; Lau J; Zhang C; Colpo N; Lin KS; Bénard F Mol Pharm; 2018 Nov; 15(11):5183-5191. PubMed ID: 30251544 [TBL] [Abstract][Full Text] [Related]
33. Synthesis and evaluation of a novel urea-based Zha Z; Ploessl K; Choi SR; Wu Z; Zhu L; Kung HF Nucl Med Biol; 2018 Apr; 59():36-47. PubMed ID: 29459281 [TBL] [Abstract][Full Text] [Related]
34. (R)-NODAGA-PSMA: A Versatile Precursor for Radiometal Labeling and Nuclear Imaging of PSMA-Positive Tumors. Gourni E; Canovas C; Goncalves V; Denat F; Meyer PT; Maecke HR PLoS One; 2015; 10(12):e0145755. PubMed ID: 26700033 [TBL] [Abstract][Full Text] [Related]
35. Hetero-bivalent agents targeting FAP and PSMA. Boinapally S; Lisok A; Lofland G; Minn I; Yan Y; Jiang Z; Shin MJ; Merino VF; Zheng L; Brayton C; Pomper MG; Banerjee SR Eur J Nucl Med Mol Imaging; 2022 Nov; 49(13):4369-4381. PubMed ID: 35965291 [TBL] [Abstract][Full Text] [Related]
36. Semiquantitative Parameters in PSMA-Targeted PET Imaging with [ Sahakyan K; Li X; Lodge MA; Werner RA; Bundschuh RA; Bundschuh L; Kulkarni HR; Schuchardt C; Baum RP; Pienta KJ; Pomper MG; Ross AE; Gorin MA; Rowe SP Mol Imaging Biol; 2020 Feb; 22(1):181-189. PubMed ID: 31115751 [TBL] [Abstract][Full Text] [Related]
37. Automated synthesis of [(18)F]DCFPyL via direct radiofluorination and validation in preclinical prostate cancer models. Bouvet V; Wuest M; Jans HS; Janzen N; Genady AR; Valliant JF; Benard F; Wuest F EJNMMI Res; 2016 Dec; 6(1):40. PubMed ID: 27142881 [TBL] [Abstract][Full Text] [Related]
38. Preclinical Evaluation and Pilot Clinical Study of Al Liu T; Liu C; Xu X; Liu F; Guo X; Li N; Wang X; Yang J; Yang X; Zhu H; Yang Z J Nucl Med; 2019 Sep; 60(9):1284-1292. PubMed ID: 30796170 [TBL] [Abstract][Full Text] [Related]
39. Semiquantitative Parameters in PSMA-Targeted PET Imaging with Li X; Rowe SP; Leal JP; Gorin MA; Allaf ME; Ross AE; Pienta KJ; Lodge MA; Pomper MG J Nucl Med; 2017 Jun; 58(6):942-946. PubMed ID: 27932557 [No Abstract] [Full Text] [Related]
40. Clinical translation of a PSMA inhibitor for Ferro-Flores G; Luna-Gutiérrez M; Ocampo-García B; Santos-Cuevas C; Azorín-Vega E; Jiménez-Mancilla N; Orocio-Rodríguez E; Davanzo J; García-Pérez FO Nucl Med Biol; 2017 May; 48():36-44. PubMed ID: 28193503 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]